WO2003068937A3 - Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells - Google Patents

Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells Download PDF

Info

Publication number
WO2003068937A3
WO2003068937A3 PCT/US2003/004539 US0304539W WO03068937A3 WO 2003068937 A3 WO2003068937 A3 WO 2003068937A3 US 0304539 W US0304539 W US 0304539W WO 03068937 A3 WO03068937 A3 WO 03068937A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
embryonic
cells
stem
post
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/004539
Other languages
French (fr)
Other versions
WO2003068937A2 (en
Inventor
Robert J Hariri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clarity Acquisition II LLC
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/076,180 external-priority patent/US20030032179A1/en
Priority to KR1020047012604A priority Critical patent/KR101176146B1/en
Priority to AU2003216286A priority patent/AU2003216286B2/en
Priority to EP03739817A priority patent/EP1482787A4/en
Priority to NZ534643A priority patent/NZ534643A/en
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Priority to MXPA04007732A priority patent/MXPA04007732A/en
Priority to JP2003568052A priority patent/JP2005517402A/en
Priority to CA002476553A priority patent/CA2476553A1/en
Publication of WO2003068937A2 publication Critical patent/WO2003068937A2/en
Publication of WO2003068937A3 publication Critical patent/WO2003068937A3/en
Priority to IL163439A priority patent/IL163439A/en
Anticipated expiration legal-status Critical
Priority to IL207763A priority patent/IL207763A/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A61M2202/0462—Placental blood, umbilical cord blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)

Abstract

The present invention provides compositions and methods of using embryonic-like stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The embryonic-like stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the embryonic-like stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The embryonic-like stem cells and the mixed populations of embryonic-like stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.
PCT/US2003/004539 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells Ceased WO2003068937A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2003568052A JP2005517402A (en) 2002-02-13 2003-02-13 Embryo-like stem cells derived from the post-partum mammalian placenta, uses of the cells and therapeutic methods using the cells
CA002476553A CA2476553A1 (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
AU2003216286A AU2003216286B2 (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
EP03739817A EP1482787A4 (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
NZ534643A NZ534643A (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
KR1020047012604A KR101176146B1 (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
MXPA04007732A MXPA04007732A (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells.
IL163439A IL163439A (en) 2002-02-13 2004-08-10 Compositions comprising embryonic-like stem cells derived from post-partum mammalian placenta and human stem or progenitor cells and kits comprising such compositions
IL207763A IL207763A (en) 2002-02-13 2010-08-24 Use of placental stem cells and umbilical cord blood cells for preparing a medicament for treating diseases and injuries

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/076,180 2002-02-13
US10/076,180 US20030032179A1 (en) 2000-12-06 2002-02-13 Post-partum mammalian placenta, its use and placental stem cells therefrom
US43729202P 2002-12-31 2002-12-31
US60/437,292 2002-12-31

Publications (2)

Publication Number Publication Date
WO2003068937A2 WO2003068937A2 (en) 2003-08-21
WO2003068937A3 true WO2003068937A3 (en) 2004-04-22

Family

ID=42186393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004539 Ceased WO2003068937A2 (en) 2002-02-13 2003-02-13 Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells

Country Status (10)

Country Link
EP (1) EP1482787A4 (en)
JP (2) JP2005517402A (en)
KR (2) KR101176146B1 (en)
AU (2) AU2003216286B2 (en)
CA (1) CA2476553A1 (en)
IL (2) IL163439A (en)
MX (1) MXPA04007732A (en)
NZ (1) NZ534643A (en)
WO (1) WO2003068937A2 (en)
ZA (1) ZA200406356B (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622108B2 (en) 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
US8889411B2 (en) 2002-04-12 2014-11-18 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US8895256B2 (en) 2005-10-13 2014-11-25 Anthrogenesis Corporation Immunomodulation using placental stem cells
US8916146B2 (en) 2007-02-12 2014-12-23 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
US8926964B2 (en) 2010-07-13 2015-01-06 Anthrogenesis Corporation Methods of generating natural killer cells
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
US9121007B2 (en) 2010-01-26 2015-09-01 Anthrogenesis Corporatin Treatment of bone-related cancers using placental stem cells
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US9149569B2 (en) 2000-12-06 2015-10-06 Anthrogenesis Corporation Treatment of diseases or disorders using placental stem cells
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
US9216200B2 (en) 2007-09-28 2015-12-22 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US9234172B2 (en) 2003-06-27 2016-01-12 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
US9254302B2 (en) 2010-04-07 2016-02-09 Anthrogenesis Corporation Angiogenesis using placental stem cells
US9339520B2 (en) 2006-10-23 2016-05-17 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
US9498501B2 (en) 2003-06-27 2016-11-22 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US9598669B2 (en) 2005-12-29 2017-03-21 Anthrogenesis Corporation Composition for collecting placental stem cells and methods of using the composition

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071283A2 (en) * 2003-02-13 2004-08-26 Anthrogenesis Corporation Use of umbilical cord blood to treat individuals having a disease, disorder or condition
US7875272B2 (en) 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
WO2005042731A1 (en) * 2003-10-31 2005-05-12 Children's Medical Center Corporation Methods for purifying hematopoietic stem cells
EP1711598A4 (en) * 2004-01-30 2009-04-08 Lifecord Inc Method for isolating and culturing multipotent progenitor/stem cells from umbilical cord blood and method for inducing differentiation thereof
US7670596B2 (en) * 2004-04-23 2010-03-02 Bioe, Inc. Multi-lineage progenitor cells
US8309070B2 (en) 2004-05-17 2012-11-13 Regents Of The University Of Minnesota Use of umbilical cord blood stem cells to treat ischemic event
WO2006015214A2 (en) * 2004-07-29 2006-02-09 Steenblock Research Institute, Inc. Umbilical cord stem cell composition & method of treating neurological diseases
CA2504451A1 (en) * 2004-08-10 2006-02-10 Geron Corporation Dendritic cell vaccines for treating cancer made from embryonic stem cells
PL1789534T3 (en) 2004-08-16 2015-03-31 Cellresearch Corp Pte Ltd Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
EP1831355A2 (en) * 2004-12-23 2007-09-12 Ethicon, Inc. Soft tissue repair and regeneration using postpartum-derived cells and cell products
WO2006071773A2 (en) * 2004-12-23 2006-07-06 Ethicon Incoporated Treatment of osteochondral diseases using postpartum-derived cells and products thereof
WO2006071778A2 (en) 2004-12-23 2006-07-06 Ethicon Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
DE602005017812D1 (en) * 2005-08-26 2009-12-31 Seoul Nat Univ Ind Foundation MULTIPOTENTIAL BLOOD CELLS FROM THE NAIL CORD AND CELL TREATMENT AGENT THEREFORE FOR THE TREATMENT OF ISCHEMIC ILLNESS
JP2007106760A (en) * 2005-09-16 2007-04-26 Kenji Yoshida Hematopoietic stem cell proliferator
US20090123560A1 (en) * 2005-09-16 2009-05-14 Kenji Yoshida Hematopoietic Stem Cell Proliferation Inducing Agent
US9388382B2 (en) 2005-10-05 2016-07-12 The Board Of Trustees Of The University Of Illinois Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
ES2454021T3 (en) 2005-10-05 2014-04-09 The Board Of Trustees Of The University Of Illinois Embryonic type stem cells isolated from human umbilical cord blood
CN101326281A (en) 2005-10-13 2008-12-17 人类起源公司 Preparation of oligodendrocytes from placenta-derived stem cells
US8048999B2 (en) * 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
WO2007070870A1 (en) 2005-12-16 2007-06-21 Ethicon, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
WO2007076522A2 (en) * 2005-12-28 2007-07-05 Ethicon, Incorporated Treatment of peripheral vascular disease using postpartum-derived cells
PT2471904T (en) * 2005-12-29 2019-02-25 Celularity Inc Placental stem cell populations
AU2014201181B2 (en) * 2005-12-29 2017-07-20 Celularity Inc. Placental stem cell populations
CN101389754A (en) * 2005-12-29 2009-03-18 人类起源公司 Co-cultivation of placental stem cells and stem cells from a second source
US9944900B2 (en) 2006-01-18 2018-04-17 Hemacell Perfusion Pulsatile perfusion extraction method for non-embryonic pluripotent stem cells
CA2646491A1 (en) * 2006-04-17 2007-10-25 Bioe, Inc. Differentiation of multi-lineage progenitor cells to respiratory epithelial cells
EP2023717B1 (en) * 2006-05-11 2016-04-13 Anthrogenesis Corporation Methods for collecting placenta cord blood stem cells
CA2666789C (en) 2006-10-18 2016-11-22 Yong Zhao Embryonic-like stem cells derived from adult human peripheral blood and methods of use
KR100812544B1 (en) * 2006-10-19 2008-03-13 재단법인서울대학교산학협력재단 Umbilical Cord Blood-derived Multipotent Stem Cells and Cell Therapy for Ischemic Necrosis Disease Containing the Same
AU2008216748A1 (en) 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and CD34+, CD45- placental stem cell-enriched cell populations
AU2014203165B2 (en) * 2007-02-12 2016-08-11 Celularity Inc. Treatment of inflammatory diseases using placental stem cells
US8673547B2 (en) 2007-03-08 2014-03-18 Hemacell Perfusion, Inc. Method for isolation of afterbirth derived cells
MX2010003019A (en) * 2007-09-19 2010-04-30 Pluristem Ltd Adherent cells from adipose or placenta tissues and use thereof in therapy.
AU2013267050B2 (en) * 2007-09-19 2016-01-07 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
CA2700613C (en) * 2007-09-26 2022-09-20 Celgene Cellular Therapeutics Angiogenic cells from human placental perfusate
KR20170116221A (en) * 2007-11-07 2017-10-18 안트로제네시스 코포레이션 Use of umbilical cord blood in the treatment of premature birth complications
KR20240052847A (en) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 Improved cell composition and methods of making the same
CN102387807A (en) 2008-12-19 2012-03-21 先进科技及再生医学有限责任公司 Treatment of Lung Diseases and Conditions
US10179900B2 (en) 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
SG174551A1 (en) 2009-03-26 2011-10-28 Ethicon Inc Human umbilical cord tissue cells as therapy for alzheimer' s disease
US8586360B2 (en) 2009-07-02 2013-11-19 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
KR20120127468A (en) 2010-01-26 2012-11-21 스템 셀즈 스핀 에스 에이 Cell homogenate from stem cells derived from growing deer antlers, a method of obtaining it and its use
JP6104896B2 (en) 2011-06-01 2017-03-29 アントフロゲネシス コーポレーション Treatment of pain using placental stem cells
AU2012358810B2 (en) 2011-12-23 2018-03-15 DePuy Synthes Products, Inc. Detection of human umbilical cord tissue-derived cells
CN115137753A (en) 2013-02-05 2022-10-04 细胞结构公司 Natural killer cells from placenta
JP2016512555A (en) * 2013-03-14 2016-04-28 アントフロゲネシス コーポレーション Use of placental stem cells in the treatment of acute kidney injury
SG11201507515YA (en) 2013-03-15 2015-10-29 Marcus Kare Torleif Larsson Cells, methods and apparatuses for umbilical cord blood collection and isolation of cells
EP3060670B1 (en) * 2013-10-24 2019-07-10 Ospedale San Raffaele S.r.l. Method
EP4008775A1 (en) 2015-03-04 2022-06-08 Mesoblast International Sàrl Cell culture method for mesenchymal stem cells
FR3035407B1 (en) 2015-04-23 2022-06-17 Francais Du Sang Ets METHOD FOR PRESERVING CELLS, TISSUES OR ORGANS IN HYPOTHERMIA
FR3040860B1 (en) * 2015-09-10 2020-05-15 Universite de Bordeaux INJECTABLE STORAGE MEDIUM FOR STORAGE OF PLACENTAL BLOOD, BONE MARROW AND PERIPHERAL BLOOD CELLS
WO2018073615A1 (en) 2016-10-21 2018-04-26 Longboat Explorers Ab Methods and compositions for generating hematopoietic cells
US12465878B2 (en) 2019-06-20 2025-11-11 Amniotics Ab Apparatus for filtering amniotic fluid
EP4234019A3 (en) 2019-10-18 2023-09-13 Amniotics AB Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861315A (en) * 1994-11-16 1999-01-19 Amgen Inc. Use of stem cell factor and soluble interleukin-6 receptor for the ex vivo expansion of hematopoietic multipotential cells
US6146888A (en) * 1993-04-21 2000-11-14 The University Of Edinburgh Method of enriching for mammalian stem cells
US6179819B1 (en) * 1996-08-30 2001-01-30 John N. Haswell Umbilical cord blood collection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
WO2001021767A2 (en) * 1999-09-24 2001-03-29 Morphogen Pharmaceuticals, Inc. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
DK1349918T3 (en) * 2000-12-06 2014-11-10 Anthrogenesis Corp Method of collecting stem cells from placenta
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146888A (en) * 1993-04-21 2000-11-14 The University Of Edinburgh Method of enriching for mammalian stem cells
US5861315A (en) * 1994-11-16 1999-01-19 Amgen Inc. Use of stem cell factor and soluble interleukin-6 receptor for the ex vivo expansion of hematopoietic multipotential cells
US6179819B1 (en) * 1996-08-30 2001-01-30 John N. Haswell Umbilical cord blood collection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG ET AL.: "Enhanced recovery of hematopoietic progenitor and stem cells from cultivated, postpartum human placenta", BLOOD, vol. 98, 16 November 2001 (2001-11-16), pages 183A, XP001085063 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149569B2 (en) 2000-12-06 2015-10-06 Anthrogenesis Corporation Treatment of diseases or disorders using placental stem cells
US8889411B2 (en) 2002-04-12 2014-11-18 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9498501B2 (en) 2003-06-27 2016-11-22 DePuy Synthes Products, Inc. Postpartum cells derived from umbilical cord tissue, and methods of making and using the same
US9234172B2 (en) 2003-06-27 2016-01-12 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US7622108B2 (en) 2004-04-23 2009-11-24 Bioe, Inc. Multi-lineage progenitor cells
US9539288B2 (en) 2005-10-13 2017-01-10 Anthrogenesis Corporation Immunomodulation using placental stem cells
US8895256B2 (en) 2005-10-13 2014-11-25 Anthrogenesis Corporation Immunomodulation using placental stem cells
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US9585918B2 (en) 2005-12-28 2017-03-07 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US9598669B2 (en) 2005-12-29 2017-03-21 Anthrogenesis Corporation Composition for collecting placental stem cells and methods of using the composition
US9339520B2 (en) 2006-10-23 2016-05-17 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
US8916146B2 (en) 2007-02-12 2014-12-23 Anthrogenesis Corporation Treatment of inflammatory diseases using placental stem cells
US9200253B1 (en) 2007-08-06 2015-12-01 Anthrogenesis Corporation Method of producing erythrocytes
US9216200B2 (en) 2007-09-28 2015-12-22 Anthrogenesis Corporation Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
US9121007B2 (en) 2010-01-26 2015-09-01 Anthrogenesis Corporatin Treatment of bone-related cancers using placental stem cells
US9254302B2 (en) 2010-04-07 2016-02-09 Anthrogenesis Corporation Angiogenesis using placental stem cells
US9464274B2 (en) 2010-07-13 2016-10-11 Anthrogenesis Corporation Methods of generating natural killer cells
US8926964B2 (en) 2010-07-13 2015-01-06 Anthrogenesis Corporation Methods of generating natural killer cells
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules

Also Published As

Publication number Publication date
JP2010059193A (en) 2010-03-18
AU2008249204B2 (en) 2011-03-10
KR20040094426A (en) 2004-11-09
AU2008249204A1 (en) 2008-12-18
IL207763A0 (en) 2010-12-30
AU2003216286B2 (en) 2008-08-28
KR20110036114A (en) 2011-04-06
JP2005517402A (en) 2005-06-16
IL163439A (en) 2011-03-31
MXPA04007732A (en) 2004-10-15
WO2003068937A2 (en) 2003-08-21
ZA200406356B (en) 2006-06-28
IL207763A (en) 2014-07-31
EP1482787A4 (en) 2006-02-15
KR101176146B1 (en) 2012-08-22
AU2003216286A1 (en) 2003-09-04
NZ534643A (en) 2010-06-25
CA2476553A1 (en) 2003-08-21
EP1482787A2 (en) 2004-12-08

Similar Documents

Publication Publication Date Title
WO2003068937A3 (en) Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells
WO2007087367A3 (en) Methods and compositions for modulating the mobilization of stem cells
ATE365045T1 (en) PRODUCTION OF SOFT AND BONE TISSUE USING PRECURSOR CELLS FROM MUSCLE, AS WELL AS ASSOCIATED COMPOSITIONS AND FORMS OF TREATMENT
T Harris Umbilical cord tissue mesenchymal stem cells: characterization and clinical applications
IL159637A (en) Composition for use in gene therapy comprising transduced cd34+ cells and their preparation
TW200740998A (en) Use of adipose tissue-derived stromal cells in spinal fusion
WO2006023803A3 (en) Methods of administering microparticles combined with autologous body components
EP2336298A3 (en) Postpartum cells derived from placental tissue and methods of making and using the same
MXPA03006699A (en) Methods of inducing organ transplant tolerance and correcting hemoglobinopathies.
AU2009240884A8 (en) Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
EA200600076A1 (en) COMPOSITIONS AND METHODS OF INCREASING THE ACTIVITY OF TELOMERASE
AU5208101A (en) Cxcr4 agonist treatment of hematopoietic cells
BR0312365A (en) Autologous human autologous progenitor mother cell culture medium, methods for the preparation thereof and a composition of human autologous progenitor mother cell and for obtaining autologous human progenitor muscle mother cells, use of an autologous human autologous progenitor culture medium human autologous progenitor mother cells, procedure for obtaining human autologous muscle progenitor mother cells and therapeutic procedure for autologous cell cardiomyoplasty, composition enriched with human autologous muscle progenitor mother cells and pharmaceutical composition
DE69634982D1 (en) PROCESS FOR INCREASING HEMATOPOIETIC CELLS
WO2024077157A3 (en) Myeloid lineages derived from pluripotent cells
WO2006078782A3 (en) Compositions containing agm cells and methods of use thereof
WO2007139939A3 (en) Methods and compositions using immunomodulatory compounds in combination therapy
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
WO2005111204A3 (en) Porcine forssman synthetase cdna and polypeptide
WO2002040640A3 (en) Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc)
WO2000061755A3 (en) Secreted human proteins
Nancarrow-Lei et al. A systemic review of the sources of adult mesenchymal stem cells and their suitability in musculoskeletal applications
WO2024077153A8 (en) Pluripotent stem cell-derived megakaryocytes and platelets
WO2006102643A3 (en) Stably transformed bone marrow-derived cells and uses thereof
Kohara et al. Tissue engineering technology to enhance cell recruitment for regeneration therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/007732

Country of ref document: MX

Ref document number: 163439

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004/06356

Country of ref document: ZA

Ref document number: 2003216286

Country of ref document: AU

Ref document number: 534643

Country of ref document: NZ

Ref document number: 2003568052

Country of ref document: JP

Ref document number: 200406356

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020047012604

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2476553

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003739817

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003739817

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 207763

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020117003297

Country of ref document: KR